Christopher Ryan Sullivan - Oct 5, 2022 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)

Role
Chief Financial Officer
Signature
/s/ Jennifer Zoltoski, by Power of Attorney
Stock symbol
AVTX
Transactions as of
Oct 5, 2022
Transactions value $
$0
Form type
4
Date filed
10/7/2022, 04:01 PM
Previous filing
Mar 10, 2022
Next filing
Feb 15, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTX Stock Option (Right to Buy) Award $0 +25K $0.00 25K Oct 5, 2022 Common Stock 25K $3.97 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option will vest in full on October 5, 2023, subject to the Reporting Person's continued service on such vesting date.